Name | Number of supported studies | Average coverage | |
---|---|---|---|
adipocyte | 8 studies | 35% ± 9% | |
pericyte | 6 studies | 22% ± 4% | |
epithelial cell | 5 studies | 23% ± 6% | |
cardiac muscle cell | 5 studies | 28% ± 5% | |
smooth muscle cell | 4 studies | 20% ± 4% | |
endothelial cell | 3 studies | 27% ± 7% | |
GABAergic neuron | 3 studies | 29% ± 10% | |
glutamatergic neuron | 3 studies | 33% ± 13% | |
transit amplifying cell | 3 studies | 24% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 22% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 5748.24 | 245 / 245 | 99% | 29.32 | 498 / 502 |
breast | 100% | 7961.07 | 459 / 459 | 99% | 30.28 | 1103 / 1118 |
stomach | 100% | 5955.23 | 359 / 359 | 98% | 20.02 | 279 / 286 |
intestine | 100% | 6745.18 | 966 / 966 | 98% | 23.14 | 514 / 527 |
pancreas | 100% | 3703.68 | 327 / 328 | 98% | 19.14 | 174 / 178 |
kidney | 100% | 5526.54 | 89 / 89 | 97% | 19.88 | 875 / 901 |
skin | 99% | 3364.82 | 1797 / 1809 | 96% | 24.03 | 454 / 472 |
bladder | 100% | 4246.67 | 21 / 21 | 93% | 15.79 | 469 / 504 |
uterus | 100% | 7387.91 | 170 / 170 | 92% | 16.23 | 420 / 459 |
lung | 100% | 4703.21 | 576 / 578 | 92% | 13.24 | 1058 / 1155 |
thymus | 100% | 6019.12 | 653 / 653 | 91% | 14.55 | 551 / 605 |
adrenal gland | 100% | 4452.51 | 258 / 258 | 89% | 13.41 | 205 / 230 |
brain | 90% | 2742.26 | 2373 / 2642 | 98% | 17.14 | 692 / 705 |
esophagus | 100% | 4246.30 | 1444 / 1445 | 82% | 14.14 | 150 / 183 |
ovary | 100% | 7224.98 | 180 / 180 | 79% | 8.98 | 341 / 430 |
liver | 92% | 1835.28 | 209 / 226 | 82% | 9.46 | 333 / 406 |
adipose | 100% | 8747.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.56 | 1 / 1 |
blood vessel | 100% | 8211.35 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 10669.58 | 859 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 25.09 | 78 / 80 |
muscle | 97% | 2020.31 | 778 / 803 | 0% | 0 | 0 / 0 |
spleen | 92% | 1756.57 | 222 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 78% | 11.25 | 35 / 45 |
peripheral blood | 6% | 106.27 | 59 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071380 | Biological process | cellular response to prostaglandin E stimulus |
GO_0006171 | Biological process | cAMP biosynthetic process |
GO_0003091 | Biological process | renal water homeostasis |
GO_0097746 | Biological process | blood vessel diameter maintenance |
GO_1904117 | Biological process | cellular response to vasopressin |
GO_0035811 | Biological process | negative regulation of urine volume |
GO_0071870 | Biological process | cellular response to catecholamine stimulus |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0010977 | Biological process | negative regulation of neuron projection development |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_1904322 | Biological process | cellular response to forskolin |
GO_0007189 | Biological process | adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0007212 | Biological process | G protein-coupled dopamine receptor signaling pathway |
GO_0032420 | Cellular component | stereocilium |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005929 | Cellular component | cilium |
GO_0005080 | Molecular function | protein kinase C binding |
GO_0004016 | Molecular function | adenylate cyclase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ADCY6 |
Protein name | Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase) Adenylate cyclase 6 |
Synonyms | KIAA0422 |
Description | FUNCTION: Catalyzes the formation of the signaling molecule cAMP downstream of G protein-coupled receptors . Functions in signaling cascades downstream of beta-adrenergic receptors in the heart and in vascular smooth muscle cells . Functions in signaling cascades downstream of the vasopressin receptor in the kidney and has a role in renal water reabsorption. Functions in signaling cascades downstream of PTH1R and plays a role in regulating renal phosphate excretion. Functions in signaling cascades downstream of the VIP and SCT receptors in pancreas and contributes to the regulation of pancreatic amylase and fluid secretion (By similarity). Signaling mediates cAMP-dependent activation of protein kinase PKA. This promotes increased phosphorylation of various proteins, including AKT. Plays a role in regulating cardiac sarcoplasmic reticulum Ca(2+) uptake and storage, and is required for normal heart ventricular contractibility. May contribute to normal heart function (By similarity). Mediates vasodilatation after activation of beta-adrenergic receptors by isoproterenol . Contributes to bone cell responses to mechanical stimuli (By similarity). . |
Accessions | ENST00000357869.8 [O43306-1] ENST00000548820.1 O43306 F8VZJ5 ENST00000307885.4 [O43306-1] ENST00000550422.5 [O43306-2] |